Saturday 25 November 2017
 
»
Tag
 
»
Hikma

Hikma posts $895 million revenue in H1

Hikma Pharmaceuticals, a fast growing multinational pharmaceutical group, has posted a revenue of $895 million for the first half of the year, marking a one per cent increase. The increase reflects the consolidation of an addition

More…

Takeda, Hikma in new licensing pact for Mena

Takeda Pharmaceuticals International, a global research company, and Hikma Pharmaceuticals, a fast growing multinational, have agreed to a new licensing agreement, expanding access to Takeda’s products in certain Mena markets.

More…

Hikma reports 24pc increase in revenue

Hikma Pharmaceuticals, a multinational pharmaceutical company, has reported a revenue of $882 million for the first half of this year, a 24 per cent increase over the same period last year. The group’s revenue includes the c

More…

Hikma reports 24pc increase in revenue

Hikma Pharmaceuticals, a multinational pharmaceutical company, has reported a revenue of $882 million for the first half of this year, a 24 per cent increase over the same period last year. The group’s revenue includes the c

More…

Hikma revenues hit $1.4bn, up 2pc

Hikma Pharmaceuticals, a leading multinational pharmaceutical group, has posted a revenue of $1.44 billion last year, up two per cent, following a strong year in 2014.   The injectables revenue climbed three per

More…

Hikma's H1 revenue hits $709m

Hikma Pharmaceuticals, the leading multinational pharmaceutical group, has reported a revenue of $709 million for the first half of the year, in line with expectations and strategic progress.   The firm has launc

More…

Hikma to acquire Roxane for $2.65bn

Hikma Pharmaceuticals, a leading multinational pharmaceutical group, is set to acquire Roxane Laboratories and Boehringer Ingelheim Roxane, from Boehringer Ingelheim. The acquisition has an aggregate value of gross consideration o

More…

Hikma in bid for Boehringer's generics unit

Jordan's Hikma Pharmaceuticals has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter. Other bidders for the US-based Boehr

More…

Hikma in bid for Boehringer's generics unit

Jordan's Hikma Pharmaceuticals has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter. Other bidders for the US-based Boehr

More…

Hikma Pharmaceuticals posts 9pc revenue increase

Hikma Pharmaceuticals, a leading multinational pharmaceutical group with operations across the Middle East and North Africa (Mena), Europe and the United States, has posted a nine per cent increase in revenue, with returns of $1.4 billion last y

More…
 1 2 3 4 5 >  Last ›

calendarCalendar of Events

Ads